NovaBay Pharmaceuticals, Inc.
NBY
$0.60
$0.0122.04%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.60% | -1.90% | -32.25% | 12.52% | -41.37% |
| Total Other Revenue | 89.29% | 70.00% | 18.18% | 0.00% | -333.33% |
| Total Revenue | 9.90% | -1.61% | -32.09% | 12.48% | -42.33% |
| Cost of Revenue | -20.73% | 3.54% | -54.99% | 13.26% | -46.08% |
| Gross Profit | 38.69% | -4.15% | -8.45% | 12.13% | -38.29% |
| SG&A Expenses | 32.87% | 12.48% | -4.77% | 14.00% | -52.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.73% | 10.16% | -24.69% | 14.06% | -50.90% |
| Operating Income | -27.88% | -52.01% | -0.19% | -16.80% | 62.51% |
| Income Before Tax | 23.04% | 10.42% | 8.28% | -129.74% | 79.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.04% | 10.42% | 8.28% | -129.74% | 79.05% |
| Earnings from Discontinued Operations | 104.65% | -- | -- | 68.53% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.50% | 31.02% | 22.15% | -84.82% | 49.94% |
| EBIT | -27.88% | -52.01% | -0.19% | -16.80% | 62.51% |
| EBITDA | -28.61% | -53.58% | -0.39% | -17.04% | 61.18% |
| EPS Basic | 99.67% | 95.44% | 96.90% | 82.95% | 69.33% |
| Normalized Basic EPS | 98.10% | 96.80% | 93.31% | 85.96% | 73.95% |
| EPS Diluted | 99.67% | 95.44% | 96.90% | 82.95% | 69.33% |
| Normalized Diluted EPS | 98.10% | 96.80% | 93.31% | 85.96% | 73.95% |
| Average Basic Shares Outstanding | 3,956.32% | 2,668.66% | 1,169.23% | 1,113.25% | 264.33% |
| Average Diluted Shares Outstanding | 3,956.32% | 2,668.66% | 1,169.23% | 1,113.25% | 264.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |